NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Seed, M, Betteridge, J, Caslake, M, Cooper, J, Humphries, S, Neil, A
Formáid:	Journal article
Foilsithe / Cruthaithe:	2009

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
de réir: Seed, M, et al.
Foilsithe / Cruthaithe: (2009)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
de réir: Neil, A, et al.
Foilsithe / Cruthaithe: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2004)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
de réir: Seed, M, et al.
Foilsithe / Cruthaithe: (2011)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
de réir: Humphries, SE, et al.
Foilsithe / Cruthaithe: (2006)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
de réir: A. David, et al.
Foilsithe / Cruthaithe: (2023-12-01)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
de réir: Humphries, SE, et al.
Foilsithe / Cruthaithe: (2005)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
de réir: Neil, A, et al.
Foilsithe / Cruthaithe: (2008)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
de réir: J. Gratton, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
de réir: Neil, A, et al.
Foilsithe / Cruthaithe: (2008)

IN APPLICABILITY OF THE CARDIOVASCULAR RISK PREDICTOR "SCORE" TO PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH)
de réir: Descamps, O, et al.
Foilsithe / Cruthaithe: (2010)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
de réir: S.E. Humphries, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Statins and familial hypercholesterolaemia.
de réir: Neil, A, et al.
Foilsithe / Cruthaithe: (2009)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
de réir: I. Tracey, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
de réir: A. Rimbert, et al.
Foilsithe / Cruthaithe: (2021-09-01)

A novel combinatorial non-viral vector to treat familial hypercholesterolaemia (FH)
de réir: Kerr, A, et al.
Foilsithe / Cruthaithe: (2016)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2005)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
de réir: J. Gratton, et al.
Foilsithe / Cruthaithe: (2023-12-01)

More evidence for inflammatory markers in predicting CHD risk
de réir: Lyford Joanna, et al.
Foilsithe / Cruthaithe: (2001-03-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
de réir: Minhas, R, et al.
Foilsithe / Cruthaithe: (2009)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
de réir: P Sharma, et al.
Foilsithe / Cruthaithe: (2012-03-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
de réir: Marks, et al.
Foilsithe / Cruthaithe: (2000-01-01)

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care
de réir: B. Iyen, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
de réir: B. Iyen, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
de réir: Marks, D, et al.
Foilsithe / Cruthaithe: (2000)

19. Using a novel combinatorial non-viral vector and small molecules to treat familial hypercholesterolaemia (FH)
de réir: Kerr, A, et al.
Foilsithe / Cruthaithe: (2016)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
de réir: Ingunn Molven, et al.
Foilsithe / Cruthaithe: (2013-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
de réir: Marks, D, et al.
Foilsithe / Cruthaithe: (2003)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
de réir: Marks, D, et al.
Foilsithe / Cruthaithe: (2002)

Familial hypercholesterolaemia
de réir: D.J. Blom
Foilsithe / Cruthaithe: (2011-01-01)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
de réir: Marks, D, et al.
Foilsithe / Cruthaithe: (2006)

The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)
de réir: F. J. Kinnear, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2000)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
de réir: E. Ofagbor, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Familial hypercholesterolaemia.
de réir: Gill, P, et al.
Foilsithe / Cruthaithe: (2012)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2004)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
de réir: Marks, D, et al.
Foilsithe / Cruthaithe: (2003)

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records
de réir: B. Iyen, et al.
Foilsithe / Cruthaithe: (2021-09-01)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

Míreanna comhchosúla

Míreanna comhchosúla